Tumor Treating Fields (TTFields) are low intensity alternating electric fields, which are tuned to interfere with the division process of cancer cells [Science of TTFields]. TTFields are delivered to the body region where the tumor is located using an investigational medical device, called the NovoTTF-100L(P) System. The system is a portable, light-weighted, battery operated device designed to deliver TTFields to the pancreatic cancer. Patients receiving TTFields need to wear four transducer arrays on their abdomen, back and flanks, which deliver the fields non-invasively to the abdomen. The system is intended for continuous home use by patients [Living with TTFields].
The NovoTTF 100L(P) System is not FDA approved to treat pancreatic cancer. Therefore, the safety and efficacy of TTFields in this condition is still unknown, and will be evaluated in this clinical trial [The PANOVA-3 Trial].
TTFields (200 kHz) have been approved by the FDA for treatment of adult patients suffering from recurrent and newly diagnosed glioblastoma.